```html

Joud’s Disease (Primary Hyperparathyroidism)

Overview

Joud’s Disease is a lay‑term name that has emerged in patient‑focused communities for primary hyperparathyroidism (PHPT), a condition in which one or more of the parathyroid glands produce too much parathyroid hormone (PTH). The excess PTH drives calcium out of bone, increases calcium absorption from the gut, and reduces calcium loss in the urine, leading to elevated serum calcium levels (hypercalcemia).

Although the disease can affect anyone, it is most common in:

• Women – especially post‑menopausal women (about 3‑4 times more common than in men).
• Adults aged 50–70 years, though it can be diagnosed at any age.

According to the CDC and NIH, PHPT is the third most common endocrine disorder after diabetes and thyroid disease, affecting roughly 1 in 1,000 adults in the United States. Prevalence rises to about 1‑2 % in people over 70 years of age.

Symptoms

Many individuals are diagnosed incidentally when routine blood work shows high calcium. When symptoms do appear, they are often vague and develop slowly, which can delay recognition. Below is a comprehensive list grouped by system.

General

• Fatigue and weakness – due to altered cellular metabolism from high calcium.
• Headache – often described as dull or pressure‑like.
• Unexplained weight loss – rare but reported in severe hypercalcemia.

Renal (Kidney) Symptoms

• Increased thirst (polydipsia) and urination (polyuria) – calcium interferes with the kidney’s ability to concentrate urine.
• Kidney stones – calcium oxalate stones are the classic presentation.
• Flank pain – may indicate a stone or, less commonly, obstruction.

Gastrointestinal Symptoms

• Nausea, vomiting, and loss of appetite.
• Abdominal pain or cramping – sometimes misdiagnosed as peptic ulcer disease.
• Constipation – a common early sign.
• Pancreatitis – rare, but high calcium can trigger pancreatic inflammation.

Skeletal Symptoms

• Bone pain – often in the hips, ribs, or long bones.
• Fractures from minimal trauma – called “fragility fractures”.
• Osteitis fibrosa cystica (Brown tumors) – severe bone demineralization seen in advanced disease.

Neuro‑psychiatric Symptoms

• Depression, anxiety, or irritability.
• Difficulty concentrating (“brain fog”).
• Memory problems.
• Confusion or delirium – usually when calcium exceeds 14 mg/dL (3.5 mmol/L).

Cardiovascular Symptoms

• High blood pressure – calcium can cause vasoconstriction.
• Palpitations or irregular heartbeat (arrhythmia).
• Shortened QT interval on ECG – a hallmark of hypercalcemia.

Causes and Risk Factors

Primary hyperparathyroidism is usually caused by a problem within the parathyroid glands themselves, not by another disease. The main etiologies are:

• Single adenoma (≈85 %) – a benign tumor that overproduces PTH.
• Hyperplasia of all four glands (≈10‑15 %) – diffuse enlargement that increases hormone output.
• Parathyroid carcinoma (≈1 %) – very rare but aggressive; often associated with very high calcium (>14 mg/dL).

Risk Factors

• Age & gender – post‑menopausal women are at highest risk.
• Family history – inherited syndromes such as Multiple Endocrine Neoplasia type 1 (MEN‑1) or type 2A (MEN‑2A) increase the chance of PHPT.
• Radiation exposure – prior neck radiation can affect gland tissue.
• Vitamin D deficiency – low vitamin D stimulates PTH secretion, which may unmask a latent adenoma.
• Chronic kidney disease (CKD) – though CKD more often causes secondary hyperparathyroidism, some CKD patients develop primary disease.

Diagnosis

Diagnosis relies on a combination of biochemical tests, imaging, and occasionally tissue diagnosis.

Laboratory Evaluation

• Serum calcium (total or ionized) – elevated in >90 % of cases (usually 10.5–12.5 mg/dL; >12.5 mg/dL is considered severe).
• Parathyroid hormone (intact PTH) level – inappropriately normal or high when calcium is high.
• Phosphate – often low to low‑normal because PTH promotes phosphate excretion.
• 25‑hydroxyvitamin D – deficiency is common; supplementation is part of management.
• Creatinine & eGFR – to assess kidney function.

Imaging Studies

• Neck ultrasound – first‑line; identifies adenomas >5 mm with >80 % sensitivity.
• Sestamibi (Tc‑99m) scan – a nuclear medicine test that highlights hyperfunctioning tissue; useful when ultrasound is equivocal.
• 4‑D CT scan – combines anatomical detail with perfusion data; increasingly used for surgical planning.
• Bone densitometry (DEXA) – assesses osteoporosis, a common consequence.
• 24‑hour urinary calcium – helps differentiate PHPT from familial hypocalciuric hypercalcemia (FHH); PHPT usually >200 mg/day.

Pathology (Rare)

If surgery removes a suspicious gland, histopathology confirms adenoma vs. carcinoma. Carcinoma shows capsular or vascular invasion.

Treatment Options

Management is individualized based on symptom severity, calcium level, age, bone density, and surgical risk.

When Surgery Is Recommended

Guidelines from the American Association of Endocrine Surgeons (AAES) and NIH suggest parathyroidectomy for:

• Serum calcium >1 mg/dL above the upper limit of normal.
• Bone density T‑score ≤ ‑2.5 at any site.
• History of nephrolithiasis (kidney stones) or reduced kidney function (eGFR <60 mL/min/1.73 m²).
• Age <50 years (even if asymptomatic) because of long‑term risk.
• Severe hypercalcemia (>14 mg/dL) or symptomatic disease.

Surgical Techniques

• Focused minimally invasive parathyroidectomy – targeted removal of the enlarged gland using pre‑operative imaging; >95 % cure rate.
• Bilateral neck exploration – traditional method; used when imaging is inconclusive.
• Intra‑operative PTH monitoring – PTH measured 10 minutes after excision; a drop >50 % confirms cure.

Medical Management (when surgery is not immediate)

1. Hydration – oral or IV saline to promote calciuresis.
2. Bisphosphonates (e.g., alendronate) – improve bone density and modestly lower calcium.
3. Calcimimetics (e.g., cinacalcet) – increase the sensitivity of calcium‑sensing receptors, reducing PTH secretion; especially useful in patients who cannot undergo surgery.
4. Vitamin D repletion – correct deficiency (cholecalciferol 800–2000 IU daily), monitoring calcium closely.
5. Loop diuretics (e.g., furosemide) – only after adequate hydration, to increase calcium excretion.

Lifestyle & Supportive Measures

• Stay well‑hydrated (≥2–3 L water/day unless contraindicated).
• Avoid excessive calcium supplements (>1,000 mg/day) unless prescribed.
• Limit high‑oxalate foods if kidney stones are a problem (e.g., spinach, nuts, tea).
• Engage in weight‑bearing exercise to protect bone health.

Living with Joud’s Disease (Primary Hyperparathyroidism)

Even after successful treatment, ongoing monitoring is essential.

Follow‑up Schedule

• Post‑operative – calcium and PTH checks at 1 week, 6 months, and 1 year.
• Long‑term – annual serum calcium, PTH, and DEXA scan every 2–3 years.

Daily Management Tips

1. Track symptoms – keep a log of fatigue, bone pain, or urinary changes.
2. Maintain a balanced diet – plenty of fruits, vegetables, and adequate protein, but moderate calcium (<1,200 mg/day).
3. Exercise regularly – 150 minutes of moderate activity per week (walking, cycling, resistance training).
4. Stay up to date with vaccines – especially flu and COVID‑19, as hypercalcemia can depress immunity.
5. Medication adherence – never stop calcium‑lowering drugs without consulting your clinician.
6. Support network – join patient groups (e.g., National Osteoporosis Foundation, Hyperparathyroidism Association) for shared experiences.

Prevention

Because primary hyperparathyroidism originates from glandular changes, true primary prevention is limited. However, you can reduce secondary contributors and detect disease early:

• Maintain adequate vitamin D levels (30–50 ng/mL) through safe sun exposure and supplements when needed.
• Keep calcium intake within recommended ranges; avoid high‑dose over‑the‑counter calcium unless directed.
• Limit excessive lithium or thiazide diuretic use, both of which can raise calcium.
• Undergo routine blood chemistry panels during annual check‑ups—early detection of mild hypercalcemia can prompt timely evaluation.

Complications

If left untreated, chronic hyperparathyroidism can lead to:

• Osteoporosis and fractures – up to 30 % of patients develop vertebral or hip fractures.
• Nephrolithiasis – recurrent kidney stones in 15‑20 % of patients.
• Chronic kidney disease – calcium deposition in renal tubules worsens renal function.
• Cardiovascular disease – hypertension, left ventricular hypertrophy, and increased coronary artery calcification.
• Neuro‑cognitive decline – persistent “brain fog” and mood disorders.
• Pancreatitis – rare but life‑threatening.
• Parathyroid carcinoma – <1 % risk, but associated with markedly high calcium and rapid symptom progression.

When to Seek Emergency Care

Prompt treatment of hypercalcemic crisis (often with IV fluids, bisphosphonates, and sometimes dialysis) can be lifesaving.

---

Sources: Mayo Clinic, Cleveland Clinic, American Association of Endocrine Surgeons Guidelines (2023), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Journal of Clinical Endocrinology & Metabolism (2022). All information reflects current knowledge as of June 2026.

```